The Value of HPV Self-Collection for Prevention and Early Detection
Cervical cancer remains one of the most preventable cancers, yet large segments of the population continue to go unscreened due to logistical, cultural, physical and geographic barriers. In response, screening programs are exploring more inclusive and accessible strategies to close these gaps.
A growing body of research supports self-collection* as a viable method of expanding participation in cervical cancer screening. Coupled with extended HPV genotyping, these methods offer new tools for identifying high-risk HPV genotypes beyond 16, 18 and 45, persistence monitoring and patient management.
This resource compendium offers clinical laboratories critical context for incorporating self-collection* and extended genotyping in HPV-based screening workflows. It brings together clinical validation data, public health motivations, and practical considerations to support broader testing strategies and risk stratification.
Download this compendium to explore:
• The clinical and public health value of self-collected* HPV samples
• How self-collection* methods compare to clinician-collected sampling
• The role of extended genotyping in risk stratification
• Considerations for implementation in high-volume labs
*In the United States, self-collected vaginal specimens, obtained in a healthcare setting, can be tested as an alternative specimen type when cervical sampling is either contraindicated or cervical samples otherwise cannot be obtained.